(NASDAQ: SAVA) Cassava Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.93%.
Cassava Sciences's earnings in 2025 is -$123,167,000.On average, 4 Wall Street analysts forecast SAVA's earnings for 2025 to be -$95,098,924, with the lowest SAVA earnings forecast at -$91,369,554, and the highest SAVA earnings forecast at -$97,895,951. On average, 3 Wall Street analysts forecast SAVA's earnings for 2026 to be -$57,157,903, with the lowest SAVA earnings forecast at -$54,916,416, and the highest SAVA earnings forecast at -$58,839,017.
In 2027, SAVA is forecast to generate $443,466,485 in earnings, with the lowest earnings forecast at $426,075,643 and the highest earnings forecast at $456,509,617.